Delveinsight
AUGUST 25, 2021
The Innovative Medicines Division focuses on Oncology, Immunology, Hepatology, Dermatology, Ophthalmology, Neuroscience, Cardiovascular, Renal and Metabolism, and Respiratory. billion followed by the other sectors such as Immunology, Hepatology, and Dermatology (USD 4.86 It generated a revenue of USD 14.71 billion), Respiratory (USD 1.9
XTalks
AUGUST 2, 2023
It is a dipeptidyl peptidase-4 inhibitor that keeps insulin levels stable and reduces the amount of glucose produced by the body. In partnership with Seagen, Sanofi will design, develop and commercialize ADCs for three cancer targets using Sanofi’s proprietary monoclonal antibody technology and Seagen’s proprietary ADC technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 23, 2021
Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.
The Pharma Data
APRIL 4, 2023
Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. Withhold KEYTRUDA depending on severity.
The Pharma Data
MARCH 11, 2021
Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.
Expert insights. Personalized for you.
98 
Let's personalize your content